Intelligence Feed event · Policy · 2026-09-13

    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy

    Question

    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy

    Direct answer

    Scholar Rock obtained FDA marketing approval for Isembyld (apitegromab-mstn), establishing the first muscle-directed therapeutic approach for patients with spinal muscular atrophy. Designed to be administered in conjunction with standard SMN-targeted regimens, the drug met primary motor function endpoints in the pivotal Phase 3 SAPPHIRE trial.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-13
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy”, revision 1, evidence through 2026-09-13. https://marketontology.com/market-events/2026-09-13/fda-approves-scholar-rock-s-isembyld-for-spinal-muscular-atrophy-4c29d0

    POLICY
    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
    Scholar Rock obtained FDA marketing approval for Isembyld (apitegromab-mstn), establishing the first muscle-directed therapeutic approach for patients with spinal muscular atrophy. Designed to be administered in conjunction with standard SMN-targeted regimens, the drug met primary motor function endpoints in the pivotal Phase 3 SAPPHIRE trial.
    SRRK
    Impact
    76
    SEP 13
    SIG
    95%
    SRRK
    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
    Scholar Rock obtained FDA marketing approval for Isembyld (apitegromab-mstn), establishing the first muscle-directed therapeutic approach for patients with spinal muscular atrophy. Designed to be administered in conjunction with standard SMN-targeted regimens, the drug met primary motor function endpoints in the pivotal Phase 3 SAPPHIRE trial.
    → FDA approval allows commercial launch of an add-on therapy in SMA, opening direct recurring drug revenue streams for SRRK.
    Impact
    Scholar Rock obtained FDA marketing approval for Isembyld (apitegromab-mstn), establishing the first muscle-directed therapeutic approach for patients with spinal muscular atrophy. Designed to be administered in conjunction with standard SMN-targeted regimens, the drug met primary motor function endpoints in the pivotal Phase 3 SAPPHIRE trial.
    Affected
    SRRK
    Transmission
    FDA approval allows commercial launch of an add-on therapy in SMA, opening direct recurring drug revenue streams for SRRK.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    SRRKcommercial product revenue generation from newly approved SMA therapeuticUp1-4wFDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month